25942 Dupilumab-associated facial dermatitis: A case series

Abstract

Recent publications have described the development of an eczematous facial rash after initiation of dupilumab, though this adverse reaction had not described in the original dupilumab atopic dermatitis clinical trials. The pathogenesis is unknown, but has been postulated to be a hypersensitivity reaction to dupilumab, an uncovered allergic contact dermatitis, rosacea, a seborrheic-like dermatitis reaction, or a treatment site–specific failure. The management of facial dermatitis after dupilumab is challenging and reports of an array of topical and systemic medications as well as clinical testing have been pursued.